timothy sykes logo
ARWR Stock Climbs As REDEMPLO Win Fuels Bullish Targets Thumbnail
G Google News

ARWR Stock Climbs As REDEMPLO Win Fuels Bullish Targets

TIM SYKES•UPDATED JUL. 22, 2026, 2:33 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Arrowhead Pharmaceuticals Inc. stocks have been trading up by 21.99 percent after promising clinical trial results fueled investor optimism.

Key Takeaways

  • European regulators cleared REDEMPLO for adults with familial chylomicronemia syndrome, adding to approvals already in the U.S., Canada, China, and Australia.
  • Phase 3 PALISADE data showed roughly 80% triglyceride cuts and an 83% drop in acute pancreatitis versus placebo in FCS patients.
  • Stifel launched coverage with a Buy and a $98 target, calling SHASTA‑3/4 in severe hypertriglyceridemia a key catalyst in a roughly $3B market.
  • JPMorgan lifted its ARWR target to $95 and sees 15%–30% upside if SHASTA‑3/4 data are strong.
  • Management will discuss Q3 2026 numbers on a 2026/08/04 webcast, with traders watching for commercialization updates.

Candlestick Chart

Live Update At 14:32:47 EDT: On Wednesday, July 22, 2026 Arrowhead Pharmaceuticals Inc. stock [NASDAQ: ARWR] is trending up by 21.99%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Arrowhead Pharmaceuticals (ARWR) has been trading like a momentum biotech with real catalysts behind it. Over the last few weeks, ARWR has climbed from about $79–$81 into the low $90s, with the latest close near $90.91 after an intraday push toward $95. That is a strong uptrend, and the daily chart shows consistent higher lows from late June through 2026/07/22.

Intraday, ARWR trading has been very active, with wide ranges right out of the open. On the latest session, the stock ripped from an $85.46 open to a $95.48 high before settling back in the low $90s. For short‑term traders, that is ideal volatility, but it also demands tight risk control.

More Breaking News

Fundamentally, ARWR is still a classic development‑stage biotech: about $829.4M in annual revenue against steep losses, with profit margins deep in the red and a negative return on equity near -44%. The company leans on its cash pile and access to capital, backed by a strong current ratio of 6.2 and roughly $1.60B in cash and short‑term investments on the balance sheet. Traders are paying up on a price‑to‑sales ratio above 16, which means ARWR is priced for future growth, not current earnings. Any stumble on the clinical or regulatory side would matter.

Why Traders Are Watching ARWR’s RNAi Momentum

ARWR has turned into a textbook catalyst stock thanks to its RNAi platform and, most recently, its rare‑disease win with REDEMPLO (plozasiran). The European Commission’s marketing authorization for REDEMPLO in familial chylomicronemia syndrome (FCS) is more than just another label. It validates Arrowhead Pharmaceuticals’ TRiM RNAi technology on a global stage and adds Europe to an approval list that already includes the U.S., Canada, China, and Australia.

For traders, the Phase 3 PALISADE data behind that approval are key. Cutting triglycerides by about 80% and slashing acute pancreatitis events by 83% versus placebo is not incremental; it is the type of efficacy that can support premium pricing and strong payer uptake in a dangerous, high‑need disease. That is why ARWR caught a modest bid after the EC decision, even though the move was not a face‑ripping squeeze. The market is starting to price in a durable revenue stream.

The Street is leaning in. Stifel initiated ARWR with a Buy and a $98 target, pointing to the SHASTA‑3/4 Phase 3 readout in severe hypertriglyceridemia as the main near‑term driver in an estimated $3B market. JPMorgan then raised its ARWR target to $95 from $88 and reiterated an Overweight rating, explicitly talking about 15%–30% upside if SHASTA‑3/4 comes in strong versus Ionis’ rival therapy.

That one‑two punch of a real product approval plus expanding price targets has turned ARWR into a name momentum traders track every day. The upcoming Q3 call on 2026/08/04 will not bring new data by itself, but it will give management a platform to talk about early REDEMPLO rollout and how they see the larger triglyceride franchise shaping up.

Conclusion

Arrowhead Pharmaceuticals now sits at an interesting crossroads. On one side, the financials show what you expect from a high‑growth biotech: negative earnings, heavy R&D spend at roughly $173.3M for the recent quarter, and a valuation that assumes big future wins. On the other side, ARWR has the kind of concrete progress many early‑stage names only dream of. REDEMPLO is approved across major regions, PALISADE delivered standout efficacy, and the Street is lining up behind the SHASTA‑3/4 readout as the next big swing.

For traders, that sets up a clear game plan. ARWR has become a catalyst‑driven, high‑beta vehicle where news flow around plozasiran and broader RNAi progress can move the chart fast. The recent grind from the upper $70s into the $90s, plus intraday ranges of $8–$10, gives both breakout traders and dip buyers room to work. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” That applies directly here: with a name this volatile, waiting for clean technical levels and well‑defined news catalysts can matter more than simply chasing price. But it also demands discipline, because any disappointment on SHASTA‑3/4 or commercialization trends would test that premium price‑to‑sales multiple.

Tim Sykes always reminds traders, “The market doesn’t care about your opinion, only your preparation.” With ARWR, preparation means knowing the REDEMPLO story, tracking the SHASTA‑3/4 timeline, and respecting the volatility on the tape. This article is for educational and research purposes only, but if you are going to trade ARWR, treat it like the catalyst‑heavy biotech it is: study the chart, understand the news, and cut losses fast when the thesis changes.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”